<div id="readability-page-1"><div><p><span>Johnson John H, Director of Xeris Biopharma Holdings Inc [XERS], filed a Form 144 on December 19, 2025 with the Securities and Exchange Commission proposing to sell restricted securities:</span></p><div><table><tbody><tr><td><span>Approximate Date Of Sale</span></td><td><span>12/19/25</span></td></tr><tr><td><span>Shares</span></td><td><span>135,402</span></td></tr><tr><td><span>Broker</span></td><td><span>Morgan Stanley Smith Barney LLC</span></td></tr></tbody></table></div><p><span>Prior to the sale of restricted stock, owners must file a Form 144 with the SEC.  Upon submission of the filing to the SEC the owner is permitted to sell the shares, or any fraction thereof, within 90 days.</span></p><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

XERS

<p>John H. Johnson, Director of Xeris Biopharma Holdings Inc, filed a Form 144 with the SEC to sell 135,402 shares of restricted stock on December 19, 2025. The sale will be conducted through Morgan Stanley Smith Barney LLC. Filing Form 144 is a prerequisite for selling restricted securities, allowing the sale within 90 days of filing.</p>

Dir Johnson Files To Sell 135,402 Of Xeris Biopharma Holdings Inc [XERS]